<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28893" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sensory Neuropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gomatos</surname>
            <given-names>Elias L.</given-names>
          </name>
          <aff>Westside Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dulebohn</surname>
            <given-names>Scott C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rehman</surname>
            <given-names>Anis</given-names>
          </name>
          <aff>District Endocrine/Sentara Northern Virginia Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elias Gomatos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Scott Dulebohn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anis Rehman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28893.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sensory neuropathies refer to a host of diseases that result in loss of sensation throughout the body. Collectively, sensory neuropathies can result from a plethora of conditions. These sensory neuropathies may be subdivided into small&#x000a0;fiber&#x000a0;pain-dominant and large fiber ataxia-predominant pathologies. Appropriate treatment and management are determined by sensory neuropathy classification, which is based on nerve size and degree of myelination. When assessing small fiber neuropathies, the small somatic A&#x003b4; and small unmyelinated C fibers are of particular interest. These fibers transmit noxious and thermal signals and regulate preganglionic sympathetic and parasympathetic function via the A&#x003b4; fibers, as well as postganglionic autonomic function via the C fibers.&#x000a0;Disruption of the normal physiological state of these fibers typically results in burning and shooting pain with paresthesia.&#x000a0;</p>
        <p>Classic clinical findings include complaints of "pins and needles" and "electricity" in the affected extremities, which follow a stocking-glove pattern.&#x000a0;Evaluation of sensory neuropathy primarily revolves around neurophysiological examination and dermatopathological studies such as skin biopsy, the current validated gold standard for diagnosing small fiber neuropathy. This activity for healthcare professionals aims to enhance learners' competence in selecting appropriate diagnostic tests, managing sensory neuropathies, and fostering effective interprofessional teamwork to improve outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiologies of sensory neuropathy.</p></list-item><list-item><p>Interpret the common physical exam findings associated with sensory neuropathy.</p></list-item><list-item><p>Implement evidence-based&#x000a0;management options available for sensory neuropathy.</p></list-item><list-item><p>Collaborate with the interprofessional team to&#x000a0;care for&#x000a0;patients with sensory neuropathy to improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28893&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28893">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28893.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sensory neuropathies refer to a host of diseases that result in loss of sensation throughout the body. Collectively, sensory neuropathies can result from a plethora of conditions. These sensory neuropathies may be subdivided into small fiber pain-dominant and large fiber ataxia-predominant pathologies.</p>
        <p>Appropriate treatment and management are determined by sensory neuropathy classification, which is based on nerve size and degree of myelination. When assessing small fiber neuropathies, the small somatic A&#x003b4; and small unmyelinated C fibers are of particular interest. These fibers transmit noxious and thermal signals and regulate preganglionic sympathetic and parasympathetic function via the A&#x003b4; fibers and postganglionic autonomic function via the C fibers.<xref ref-type="bibr" rid="article-28893.r1">[1]</xref>&#x000a0;Disruption of the normal physiological state of these fibers typically results in burning and shooting pain with paresthesia.</p>
        <p>In contrast, large fiber neuropathies result from attenuating A&#x003b2; fibers, which regulate the proprioceptive signals of vibration and touch. Grossly speaking, patients with sensory ataxia likely possess deformation to the dorsal columns of the spinal cord as well as the dorsal root ganglia.<xref ref-type="bibr" rid="article-28893.r2">[2]</xref>&#x000a0;Although ataxia is pathognomonic for large-fiber sensory neuropathy, subsequent damage to smaller fibers may occur. As such, some diseases may yield mixed etiology polyneuropathies, composed of small and large fibers (eg, diabetes mellitus), and present some of the most significant public health burdens in modern-day medicine.<xref ref-type="bibr" rid="article-28893.r3">[3]</xref><xref ref-type="bibr" rid="article-28893.r4">[4]</xref></p>
        <p>Classic clinical findings include complaints of "pins and needles" and "electricity" in the affected extremities, which follow a stocking-glove pattern.<xref ref-type="bibr" rid="article-28893.r5">[5]</xref>&#x000a0;Evaluation of sensory neuropathy primarily revolves around neurophysiological examination and dermatopathological studies such as skin biopsy, the current validated gold standard for diagnosing small fiber neuropathy.<xref ref-type="bibr" rid="article-28893.r6">[6]</xref>&#x000a0;Guidelines on specific treatment modalities for sensory neuropathies have not been defined. The majority of the data regarding treatments are based on expert opinions, along with well-constructed research. Treatments include injection of intravenous immunoglobulins, methotrexate, corticosteroids, infliximab, plasma exchange, and&#x000a0;various oral topical medications, depending on the etiology.<xref ref-type="bibr" rid="article-28893.r7">[7]</xref>&#x000a0;This activity reviews the evaluation and management of patients with sensory neuropathies.</p>
      </sec>
      <sec id="article-28893.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Recognizing the varying causative factors directly associated with sensory neuropathy is paramount to providing prompt and effective treatment as a clinician. When generating differential diagnoses, a direct causative factor may not be readily apparent, and a diagnosis of exclusion (ie, idiopathic sensory neuropathy) must merit consideration, as this constitutes&#x000a0;20% to 30% of cases.<xref ref-type="bibr" rid="article-28893.r8">[8]</xref>&#x000a0;Clinicians should consider a comprehensive list of potential underlying etiologies, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Immune-mediated conditions</bold>: sarcoidosis, Sj&#x000f6;gren syndrome, systemic lupus erythematosus, celiac disease</p>
          </list-item>
          <list-item>
            <p><bold>Metabolic</bold>: diabetes mellitus, hyperlipidemia</p>
          </list-item>
          <list-item>
            <p><bold>Nutritional deficiencies</bold>: vitamin B12, copper, vitamin E, folic acid&#x000a0;<xref ref-type="bibr" rid="article-28893.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Toxic</bold>: chemotherapy, drug-induced, alcohol</p>
          </list-item>
          <list-item>
            <p><bold>Hereditary</bold>: hemochromatosis, Fabry disease, Ehlers-Danlos syndrome, Friedreich ataxia</p>
          </list-item>
          <list-item>
            <p><bold>Infectious</bold>: herpes simplex, varicella-zoster virus,&#x000a0;leprosy, HIV, hepatitis C, cryoglobulinemia</p>
          </list-item>
          <list-item>
            <p><bold>Other</bold>: idiopathic, fibromyalgia, vasculitis&#x000a0;<xref ref-type="bibr" rid="article-28893.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28893.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Studies that have assessed the incidence of sensory neuropathy in the general population report a range of 1% to 3% prevalence, with an increase of up to 7% in older adults.<xref ref-type="bibr" rid="article-28893.r8">[8]</xref>&#x000a0;Studies have shown that developing countries exhibit a lower prevalence, which may, in part, be due to variations in life expectancy. From a global perspective, Western countries are most commonly affected, with a slight preference towards females.&#x000a0;In developing countries, infectious diseases like leprosy are the predominant causes of neuropathy. In contrast, in Western countries, polyneuropathy is predominantly associated with several conditions, including diabetes, alcohol overconsumption, cytostatic drugs, and cardiovascular disease.<xref ref-type="bibr" rid="article-28893.r8">[8]</xref></p>
        <p>From a public health standpoint, clinicians should be aware that diabetes mellitus is the leading cause of peripheral neuropathy worldwide.<xref ref-type="bibr" rid="article-28893.r10">[10]</xref> Up to 50% of older patients with diabetes mellitus will acquire some form of distal peripheral neuropathy, which affects their sense of pain and temperature discrimination. A pioneering orthopedic surgeon, Dr. Paul Brand, was renowned for his work on neuropathy, which was inspired after working in India, where he noticed that the loss of peripheral sensation ("gift of pain") was the reason his patients with Hansen disease suffered from severe scarring and ulceration. Similarly, in the diabetic population, distal peripheral neuropathy is a major risk factor in developing diabetic foot complications.<xref ref-type="bibr" rid="article-28893.r11">[11]</xref><xref ref-type="bibr" rid="article-28893.r12">[12]</xref></p>
      </sec>
      <sec id="article-28893.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of sensory neuropathy varies according to the cause, including:</p>
        <p><bold>Diabetes</bold>:<bold>&#x000a0;</bold>Excess glucose and lipids lead to oxidative stress, which damages mitochondria and disrupts normal cellular function. Nerve ischemia and impaired nerve fiber repair also contribute to diabetic neuropathy. These metabolic impairments lead to a vicious cycle of ROS accumulation, reduced antioxidant defense, and peripheral nerve damage.<xref ref-type="bibr" rid="article-28893.r13">[13]</xref></p>
        <p><bold>Guillain-Barr&#x000e9; syndrome</bold>: This neuropathy&#x000a0;is predominantly demyelinating, but axonal forms also exist, such as acute motor axonal polyneuropathy (AMAN), where the primary invasion of axons by inflammatory cells.<xref ref-type="bibr" rid="article-28893.r14">[14]</xref></p>
        <p><bold>Uremic</bold>
<bold>polyneuropathy</bold>:<bold>&#x000a0;</bold>Demyelination and axonal degeneration characterize this neuropathy. The cause is unknown, but it may be related to thiamine, zinc, biotin deficiencies, and decreased transketolase activity.<xref ref-type="bibr" rid="article-28893.r15">[15]</xref> Other contributing factors include increases in phenols, myoinositol, beta2-microglobulin, hyperparathyroidism, and hyperkalemia. The changes are most severe distally, and longer axons are affected first.<xref ref-type="bibr" rid="article-28893.r16">[16]</xref></p>
        <p><bold>Vitamin B12 deficiency</bold>: Sensory neuropathy can be caused by this vitamin deficiency due to myelin production interference, the fatty substance that surrounds and insulates nerves. Without enough myelin, nerve signals are not transmitted efficiently, leading to the symptoms of sensory neuropathy.</p>
        <p><bold>Environmental</bold>:&#x000a0;Environmental factors can significantly impact nerve health, causing disorders primarily affecting&#x000a0;axons. For example, neuropathies resulting from prolonged exposure to cold, vibration-induced nerve damage, or hypoxemia are well-documented.<xref ref-type="bibr" rid="article-28893.r17">[17]</xref></p>
        <p><bold>Sarcoidosis</bold>: Sensory neuropathy in sarcoidosis is believed to be caused by infiltrating granulomas in peripheral nerves. The granulomas can compress or disrupt the normal function of sensory nerves, leading to sensory abnormalities (eg, tingling and numbness).<xref ref-type="bibr" rid="article-28893.r18">[18]</xref>&#x000a0;</p>
        <p><bold>Varicella-zoster virus</bold>:&#x000a0;The virus can enter the sensory ganglia and establish latency, leading to chronic inflammation and nerve damage. This can result in sensory neuropathy and characteristic symptoms of pain, tingling, and numbness.<xref ref-type="bibr" rid="article-28893.r19">[19]</xref></p>
      </sec>
      <sec id="article-28893.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>One of the most distinct symptoms of sensory neuropathy is early-onset ataxia, mainly due to the disruption of the afferent neurons, which transmit impulses from the body's extremities.<xref ref-type="bibr" rid="article-28893.r20">[20]</xref> If these symptoms progress, resultant "writhing" movements will manifest in the hands and feet as the patient closes their eyes.&#x000a0;Positive sensory symptoms are also common when small- and medium-sized fibers are affected.&#x000a0;Classic clinical findings include complaints of "pins and needles" and "electricity" in the affected extremities, which follow a stocking-glove pattern.<xref ref-type="bibr" rid="article-28893.r5">[5]</xref> Especially in people with diabetes, a clinician must be vigilant in assessing for negative neuropathic symptoms manifest in small-fiber neuropathies. Numbness, a negative neuropathic symptom, is commonly seen in the feet and is non-length dependent and multifocal.</p>
        <p>When performing a clinical history, variability in disease progression will be significant. Subacute sensory neuropathies are commonly seen in immune-mediate and post-infectious cases, whereas idiopathic variants are more stagnant.<xref ref-type="bibr" rid="article-28893.r21">[21]</xref> In many cases, motor weakness does not accompany sensory neuropathy. However, the motor output may be affected in those with paraneoplastic sensory neuropathies, resulting in absent stretch reflexes.</p>
      </sec>
      <sec id="article-28893.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Neurophysiological and Dermatopathological Diagnostic Studies</bold>
</p>
        <p>Evaluation of sensory neuropathy primarily revolves around neurophysiological examination and dermatopathological studies such as skin biopsy. When diagnosing small fiber neuropathies, electromyography (EMG) results may appear normal, and the presence of sural and plantar responses does not exclude purely small fiber neuropathy. In EMG studies, sensory neuropathies mostly demonstrate a reduced or absent sensory nerve action potential.<xref ref-type="bibr" rid="article-28893.r22">[22]</xref>&#x000a0;For patients with diabetic peripheral sensory neuropathy, a Semmes-Weinstein 5.07 monofilament nylon test is often performed at varying locations of the foot to test for a protective threshold previously defined as 10 g of force.<xref ref-type="bibr" rid="article-28893.r23">[23]</xref></p>
        <p>Demyelination is linked to a reduction in conduction velocity, which is slower than 75% of the lower limit of normal. Additionally, it can cause marked prolongation of distal latency, which is longer than 130% of the upper limit of normal. Demyelination can also result in amplitude changes due to secondary axonal loss. Demyelination can occur in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy.<xref ref-type="bibr" rid="article-28893.r24">[24]</xref></p>
        <p>Regarding autonomic sensory testing, quantitative exams assess for hot and cold sensations, transient changes in the electrical potential of the skin (eg, sweat gland activity), and noninvasive electrochemical skin conductance studies to detect sudomotor dysfunction.<xref ref-type="bibr" rid="article-28893.r25">[25]</xref> Some of the most valuable studies for small fiber-dominant neuropathy are thermoregulatory sweat testing and the quantitative sudomotor axon reflex test. Though these studies are not readily available, recent literature shows that their clinical additions yield higher diagnostic success.<xref ref-type="bibr" rid="article-28893.r26">[26]</xref></p>
        <p>The current validated gold standard for diagnosing small fiber neuropathy is a skin biopsy.<xref ref-type="bibr" rid="article-28893.r6">[6]</xref>&#x000a0;Depending on the research, sensitivities for skin biopsy can be as high as 90%,&#x000a0;with specificities as high as 97%.<xref ref-type="bibr" rid="article-28893.r27">[27]</xref>&#x000a0;The benefits of skin biopsy include ease of use and low morbidity. Common sites of the acquisition include the distal leg, just 10 cm proximal to the lateral malleolus, and the lateral distal or proximal thigh.&#x000a0;In general, nerve biopsy is not necessary to diagnose sensory neuropathy.</p>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>Imaging studies are also used to evaluate sensory neuropathies and are of greatest utility when assessing paraneoplastic etiologies. Magnetic resonance imaging and its analogs, inversion recovery MRI pulse sequencing, and T2-weighted spoiled gradient-echo sequencing are particularly useful in visualizing dorsal column pathology.<xref ref-type="bibr" rid="article-28893.r28">[28]</xref></p>
      </sec>
      <sec id="article-28893.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Guidelines on specific treatment modalities for sensory neuropathies have not been defined. The majority of the data regarding treatments are based on expert opinions, along with well-constructed research. Treatments include injection of intravenous immunoglobulins, methotrexate, corticosteroids, infliximab, plasma exchange, and various oral topical medications, depending on the etiology.<xref ref-type="bibr" rid="article-28893.r7">[7]</xref> Recent data suggest that sensory symptomatology generally plateaus after 7&#x000a0;to 10 months.<xref ref-type="bibr" rid="article-28893.r29">[29]</xref> If possible, treatment protocols should be initiated within this period.</p>
        <p>The efficacy of various oral medications, including anticonvulsants (eg, pregabalin and oxcarbazepine), serotonin-norepinephrine reuptake inhibitors (eg, duloxetine and venlafaxine), tricyclic antidepressants, opioids (eg, tramadol and tapentadol), and botulinum toxin A with and without chemodenervation have demonstrated more effectiveness than a placebo in numerous randomized controlled trials.<xref ref-type="bibr" rid="article-28893.r30">[30]</xref><xref ref-type="bibr" rid="article-28893.r31">[31]</xref>&#x000a0;The American Academy of Neurology has also recommended topical agents (eg, lidocaine and capsaicin).</p>
        <p>Future clinical avenues for research are promising for the utility of physical exercise in sensory neuropathy secondary to diabetes mellitus. Some current studies show increased nerve fiber density in patients with diabetes mellitus and measured pain response to exercise in those with established neuropathy.<xref ref-type="bibr" rid="article-28893.r32">[32]</xref><xref ref-type="bibr" rid="article-28893.r33">[33]</xref>&#x000a0;Results such as these are encouraging and much warranted as the general etiologies of sensory neuropathy are considered rare compared to those cases caused by diabetes mellitus, which is far more widespread.</p>
        <p>
<bold>Sensory Neuropathy Management</bold>
</p>
        <p>The following are some management strategies for specified neuropathies.&#x000a0;See StatPearls' companion topics on the following neuropathies for&#x000a0;detailed management information.<xref ref-type="bibr" rid="article-28893.r34">[34]</xref><xref ref-type="bibr" rid="article-28893.r35">[35]</xref><xref ref-type="bibr" rid="article-28893.r36">[36]</xref></p>
        <p><bold>Diabetic neuropathy</bold>: The management involves tight glycemic control, risk factor management, and symptom control. Tight glycemic control includes maintaining blood glucose levels within a target range. Risk factor management involves addressing factors such as hypertension, hyperlipidemia, and smoking. Symptom control can be achieved using medications such as duloxetine, amitriptyline, pregabalin, and gabapentin, along with lifestyle modifications and physical therapy. Amitriptyline should be avoided in patients with benign prostatic hyperplasia as it can cause urinary retention.</p>
        <p><bold>Guillain-Barre syndrome</bold>: Management&#x000a0;includes physical therapy, pain management, and assistive devices. In severe cases, intravenous immunoglobulin or plasmapheresis may reduce inflammation and improve outcomes.</p>
        <p><bold>Uremic polyneuropathy</bold>: The most&#x000a0;crucial management plan is to&#x000a0;control underlying conditions contributing to the development of uremic polyneuropathy, such as diabetes and hypertension. Medications that may be used to manage symptoms of Uremic polyneuropathy include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gabapentin</p>
          </list-item>
          <list-item>
            <p>Pregabalin</p>
          </list-item>
          <list-item>
            <p>Duloxetine</p>
          </list-item>
          <list-item>
            <p>Tricyclic antidepressants (eg, amitriptyline)</p>
          </list-item>
          <list-item>
            <p>Opioids (eg, tramadol)</p>
          </list-item>
        </list>
        <p><bold>Vitamin B12 deficiency</bold>:&#x000a0;This neuropathy is managed through replacement with vitamin B12 supplementation.</p>
        <p><bold>Chronic inflammatory demyelinating&#x000a0;neuropathy</bold>:&#x000a0;Corticosteroids are used to treat this neuropathy initially but can also be treated using intravenous immunoglobulin, plasma exchange, and some immunosuppressant drugs.</p>
      </sec>
      <sec id="article-28893.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Sensory neuropathy can have various underlying causes. Differential diagnoses that should be considered include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic neuropathy</p>
          </list-item>
          <list-item>
            <p>Alcohol neuropathy</p>
          </list-item>
          <list-item>
            <p>Guillain-Barre syndrome</p>
          </list-item>
          <list-item>
            <p>Charcot-Marie-Tooth disease</p>
          </list-item>
          <list-item>
            <p>Autoimmune neuropathy</p>
          </list-item>
          <list-item>
            <p>HIV-associated neuropathy</p>
          </list-item>
          <list-item>
            <p>Nutritional deficiencies (eg, vitamin B12 deficiency)</p>
          </list-item>
          <list-item>
            <p>Infectious neuropathy (eg, Lyme disease or leprosy)</p>
          </list-item>
          <list-item>
            <p>Toxin-induced neuropathy (eg, arsenic or lead poisoning)</p>
          </list-item>
        </list>
        <p>In a substantial portion of patients, the exact cause of sensory neuropathy is not readily apparent, and the disease is considered idiopathic.<xref ref-type="bibr" rid="article-28893.r37">[37]</xref> Literature suggests that idiopathic sensory neuropathy is a diagnosis of exclusion and that there may be an autoimmune component of the pathophysiology behind the disease.<xref ref-type="bibr" rid="article-28893.r38">[38]</xref>&#x000a0;Other diseases that may present in a similar clinical fashion include distal acquired demyelinating symmetric neuropathy and sensory chronic inflammatory demyelinating polyradiculoneuropathy. These symptoms may also mimic other radiculopathies, myelopathies, and autoimmune diseases.</p>
      </sec>
      <sec id="article-28893.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <table-wrap id="article-28893.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. Commonly Used Drugs in Sensory Neuropathy</title>
          </caption>
          <table style="width: 800px;" border="1" cellpadding="1">
            <tbody>
              <tr style="height: 13px;">
                <td style="height: 13px; width: 131px;" rowspan="1" colspan="1">
<p><bold>Drug</bold></p>
</td>
                <td style="height: 13px; width: 147.85px;" rowspan="1" colspan="1">
<bold>Mechanism</bold>
</td>
                <td style="height: 13px; width: 169.15px;" rowspan="1" colspan="1">
<bold>Initial Dose</bold>
</td>
                <td style="height: 13px; width: 166px;" rowspan="1" colspan="1">
<bold>Maximum Dose</bold>
</td>
                <td style="height: 13px; width: 161px;" rowspan="1" colspan="1">
<bold>Adverse&#x000a0;Effects</bold>
</td>
              </tr>
              <tr style="height: 39px;">
                <td style="height: 39px; width: 131px;" rowspan="1" colspan="1">
<bold>Gabapentin&#x000a0;</bold>
<xref ref-type="bibr" rid="article-28893.r39">[39]</xref>
</td>
                <td style="height: 39px; width: 147.85px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Calcium channel alpha-2-delta subunit blocker</p></list-item></list>
</td>
                <td style="height: 39px; width: 169.15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>300 mg/day</p></list-item></list>
</td>
                <td style="height: 39px; width: 166px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>3600 mg/day in divided doses</p></list-item></list>
</td>
                <td style="height: 39px; width: 161px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Dizziness</p></list-item><list-item><p>Drowsiness</p></list-item><list-item><p>Peripheral edema</p></list-item><list-item><p>Constipation</p></list-item><list-item><p>Dry mouth</p></list-item><list-item><p>Flatulence</p></list-item><list-item><p>Hypertension</p></list-item><list-item><p>Insomnia</p></list-item><list-item><p>Memory loss</p></list-item></list>
</td>
              </tr>
              <tr style="height: 39px;">
                <td style="height: 39px; width: 131px;" rowspan="1" colspan="1">
<p><bold>Pregabalin&#x000a0;</bold><xref ref-type="bibr" rid="article-28893.r40">[40]</xref></p>
</td>
                <td style="height: 39px; width: 147.85px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Calcium channel alpha-2-delta subunit blocker</p></list-item></list>
</td>
                <td style="height: 39px; width: 169.15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>150 mg/day in 2-3 divided doses</p></list-item></list>
</td>
                <td style="height: 39px; width: 166px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>600 mg/day in 2-3 divided doses</p></list-item></list>
</td>
                <td style="height: 39px; width: 161px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Dizziness</p></list-item><list-item><p>Drowsiness</p></list-item><list-item><p>Peripheral edema</p></list-item><list-item><p>Sexual dysfunction</p></list-item><list-item><p>Impaired concentration</p></list-item><list-item><p>Diarrhea</p></list-item><list-item><p>Vision disorders</p></list-item></list>
</td>
              </tr>
              <tr style="height: 39px;">
                <td style="height: 39px; width: 131px;" rowspan="1" colspan="1">
<bold>Duloxetine&#x000a0;</bold>
<xref ref-type="bibr" rid="article-28893.r41">[41]</xref>
</td>
                <td style="height: 39px; width: 147.85px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Serotonin-norepinephrine reuptake inhibitor</p></list-item></list>
</td>
                <td style="height: 39px; width: 169.15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>30 mg/day</p></list-item></list>
</td>
                <td style="height: 39px; width: 166px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>60-120 mg/day</p></list-item></list>
</td>
                <td style="height: 39px; width: 161px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Nausea</p></list-item><list-item><p>Somnolence</p></list-item><list-item><p>Anxiety</p></list-item><list-item><p>Yawning</p></list-item><list-item><p>Constipation</p></list-item><list-item><p>Dry mouth</p></list-item></list>
</td>
              </tr>
              <tr style="height: 39px;">
                <td style="height: 39px; width: 131px;" rowspan="1" colspan="1">
<bold>Amitriptyline&#x000a0;</bold>
<xref ref-type="bibr" rid="article-28893.r42">[42]</xref>
</td>
                <td style="height: 39px; width: 147.85px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Tricyclic antidepressant</p></list-item></list>
</td>
                <td style="height: 39px; width: 169.15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10-25 mg at bedtime, dose increased in steps of 10-25 mg every 3-7 days in 1-2 divided doses</p></list-item></list>
</td>
                <td style="height: 39px; width: 166px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>100 mg at bedtime; doses above 100 mg should be used with caution in older adults, with a maximum per dose of 75 mg</p></list-item></list>
</td>
                <td style="height: 39px; width: 161px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Dry mouth</p></list-item><list-item><p>Constipation</p></list-item><list-item><p>Blurred vision</p></list-item><list-item><p>Anticholinergic syndrome</p></list-item><list-item><p>QT interval prolongation</p></list-item><list-item><p>Breast enlargement</p></list-item><list-item><p>Cardiac disorders</p></list-item><list-item><p>Conduction disorders</p></list-item><list-item><p>Galactorrhea</p></list-item><list-item><p>Hepatic disorders</p></list-item><list-item><p>SIADH</p></list-item></list>
</td>
              </tr>
              <tr style="height: 26px;">
                <td style="height: 26px; width: 131px;" rowspan="1" colspan="1">
<bold>Carbamazepine&#x000a0;</bold>
<xref ref-type="bibr" rid="article-28893.r43">[43]</xref>
</td>
                <td style="height: 26px; width: 147.85px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sodium channel blocker</p></list-item></list>
</td>
                <td style="height: 26px; width: 169.15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>100 mg twice daily</p></list-item></list>
</td>
                <td style="height: 26px; width: 166px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>800-1600 mg/day</p></list-item></list>
</td>
                <td style="height: 26px; width: 161px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Dizziness</p></list-item><list-item><p>Drowsiness</p></list-item><list-item><p>Nausea</p></list-item><list-item><p>Hyponatremia</p></list-item><list-item><p>Leukopenia movement disorders</p></list-item><list-item><p>Thrombocytopenia</p></list-item><list-item><p>Vision disorders</p></list-item><list-item><p>Weight gain</p></list-item><list-item><p>Edema</p></list-item><list-item><p>Skin reactions</p></list-item></list>
</td>
              </tr>
              <tr style="height: 26px;">
                <td style="height: 26px; width: 131px;" rowspan="1" colspan="1">
<bold>Oxcarbazepine&#x000a0;</bold>
<xref ref-type="bibr" rid="article-28893.r44">[44]</xref>
</td>
                <td style="height: 26px; width: 147.85px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sodium channel blocker</p></list-item></list>
</td>
                <td style="height: 26px; width: 169.15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>300 mg twice daily</p></list-item></list>
</td>
                <td style="height: 26px; width: 166px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2400 mg/day in divided dosages</p></list-item></list>
</td>
                <td style="height: 26px; width: 161px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Dizziness</p></list-item><list-item><p>Drowsiness</p></list-item><list-item><p>Nausea</p></list-item><list-item><p>Agitation</p></list-item><list-item><p>Abdominal pain</p></list-item><list-item><p>Ataxia</p></list-item><list-item><p>Emotional lability</p></list-item><list-item><p>Skin reactions</p></list-item><list-item><p>Vertigo</p></list-item><list-item><p>Vision disorders</p></list-item><list-item><p>Vomiting</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-28893.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Outcomes for patients who suffer from different forms of sensory neuropathy will vary. When Wallerian degeneration occurs, a series of events leads to complete structural and chemical disintegration of the nerve, resulting in a more guarded prognosis. Recovery is contingent on the regeneration of the nerve, depending largely upon how well the transected nerve endings are aligned, as well as the severity of any adjacent soft tissue injury and scarring. To achieve a noticeable clinical outcome, the affected muscles and organs must become reinnervated after adequate nerve regeneration and remyelination occurs. If the pathology causing any sensory neuropathic symptoms is purely due to segmental demyelination, the prognosis will be much more positive. This is because it entails a shorter recovery and quicker return to function. Pain and temperature are typically the first sensations to recover.</p>
        <p>Regarding those patients with glucose dysregulation, monitoring their hemoglobin A1c lab values is vital to track the progression of the disease. Current recommendations from the American Diabetes Association underscore maintenance of a value less than 7% in conjunction with a healthy lifestyle (ie, diet and exercise) for those with established diabetes.<xref ref-type="bibr" rid="article-28893.r45">[45]</xref></p>
      </sec>
      <sec id="article-28893.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The results can be debilitating if sensory neuropathy is not managed within an acute time frame. Patients will often suffer from varying degrees of burns and other traumatic dermal injuries due to the lack of protective sensation. This sensory loss, in turn, increases the risk of infection secondary to these traumatic events, as these injuries are usually not treated quickly and efficiently. In older populations, the risk of accidental falls increases as balance and strength diminish.</p>
        <p>Again, in patients with diabetes mellitus who present with concomitant sensory neuropathy, the complications are significant and life-altering. As a protective threshold is lost, it is not uncommon for patients to step on a sharp object such as glass or a rusty nail and remain unaware until they notice bleeding from their socks. These injuries are prevalent in the emergency room and constitute a significant challenge for the medical team.</p>
        <p>Severe infections leading to sepsis and gangrene of the lower extremities due to chronic neuropathic ulcerations or retention of a foreign body is a leading cause of amputation in people with diabetes. The overall risk of developing diabetic foot ulceration is around 2% per year; that statistic increases to about 7% in those with sensory neuropathy, a staggering causal finding.<xref ref-type="bibr" rid="article-28893.r12">[12]</xref>&#x000a0;Proper patient education with a communicative multidisciplinary healthcare team mitigates these risks.</p>
      </sec>
      <sec id="article-28893.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>To effectively deter the course of this disease, clinicians must adequately educate patients on the potential signs and symptoms previously discussed. Making necessary alterations in daily life is equally important if a patient does begin to notice symptoms. Patients with established sensory neuropathy should limit their exposure to temperature extremes and monitor sudden, apparent changes in gait patterns to diminish the effects of repetitive micro-motion to their feet; modifications in shoe gear may also be necessary.</p>
        <p>For diabetic patients, an established daily foot screening protocol should be performed daily for early detection of possible lesions. These patients should also schedule frequent visits with their podiatric physician at least every 2&#x000a0;to 3 months for formal evaluation and care as part of a holistic approach to managing their sensory neuropathy. A primary care physician or an endocrinologist also plays a vital role in the overall management of diabetes and the limitation of sensory neuropathy symptomatology.</p>
      </sec>
      <sec id="article-28893.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sensory neuropathy involves dysfunction of peripheral nerves, leading to abnormal sensations or loss of sensation. Clinicians must recognize diverse etiologies, including diabetes, infections, and autoimmune disorders. Diagnosis relies on patient history, examination, and, if necessary, nerve conduction studies. Management focuses on treating the underlying cause, symptomatic relief, and lifestyle modifications. Regular monitoring for complications and patient education on self-care are essential. A holistic approach, considering physical and emotional aspects, is crucial for optimal patient outcomes in sensory neuropathy, a condition impacting sensory perception with potential wide-ranging effects on daily life.</p>
        <p>The availability of healthcare is not genuinely ubiquitous in all parts of the world, and strides are necessary to provide evidence-based treatment via an interprofessional team approach to those in need. As patient education is essential in the prevention of sensory neuropathy-related morbidities, so are the neurologists, vascular surgeons, physical and occupational therapists, infectious disease specialists, endocrinologists, and podiatric physicians, who each provide essential tools from their armamentaria to combat this disease and its symptoms.</p>
      </sec>
      <sec id="article-28893.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28893&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28893">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/sensory-neuropathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28893">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28893/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28893">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28893.s16">
        <title>References</title>
        <ref id="article-28893.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoeijmakers</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lauria</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Merkies</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Waxman</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Small-fibre neuropathies--advances in diagnosis, pathophysiology and management.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2012</year>
            <month>May</month>
            <day>29</day>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>369</fpage>
            <page-range>369-79</page-range>
            <pub-id pub-id-type="pmid">22641108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soh Weng Yan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooney</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Akhtar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maheswaran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A Case of Subacute Degeneration of the Spinal Cord Due to Vitamin B12 Deficiency Triggered by Nitrous Oxide Use.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>e48312</fpage>
            <pub-id pub-id-type="pmid">37933319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Boulton</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Kirsner</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Attinger</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Lavery</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <source>Diagnosis and Management of Diabetic Foot Complications</source>
            <publisher-name>American Diabetes Association</publisher-name>
            <publisher-loc>Arlington (VA)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <pub-id pub-id-type="pmid">30958663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elafros</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Callaghan</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Diabetic Neuropathies.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2023</year>
            <month>Oct</month>
            <day>01</day>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>1401</fpage>
            <page-range>1401-1417</page-range>
            <pub-id pub-id-type="pmid">37851036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anastasi</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Capili</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>An Analysis of Peripheral Neuropathy Symptom Characteristics in HIV.</article-title>
            <source>J Med Healthc</source>
            <year>2022</year>
            <volume>4</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35174365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>England</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Kinsella</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Asbury</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Szigeti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lupski</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Latov</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lauria</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Polydefkis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sumner</surname>
                <given-names>AJ</given-names>
              </name>
              <collab>American Academy of Neurology</collab>
              <collab>American Association of Neuromuscular and Electrodiagnostic Medicine</collab>
              <collab>American Academy of Physical Medicine and Rehabilitation</collab>
            </person-group>
            <article-title>Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.</article-title>
            <source>PM R</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-22</page-range>
            <pub-id pub-id-type="pmid">19627868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tavee</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Karwa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Parambil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Culver</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment.</article-title>
            <source>Respir Med</source>
            <year>2017</year>
            <month>May</month>
            <volume>126</volume>
            <fpage>135</fpage>
            <page-range>135-138</page-range>
            <pub-id pub-id-type="pmid">28318820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanewinckel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Oijen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ikram</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>van Doorn</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology and risk factors of chronic polyneuropathy.</article-title>
            <source>Eur J Epidemiol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-20</page-range>
            <pub-id pub-id-type="pmid">26700499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ginsberg</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Vasculitis and the peripheral nervous system.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>59</volume>
            <issue>Suppl 3</issue>
            <fpage>iii55</fpage>
            <page-range>iii55-iii59</page-range>
            <pub-id pub-id-type="pmid">32348511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robinson Singleton</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic neuropathy, prediabetes and the metabolic syndrome.</article-title>
            <source>J Neurol Sci</source>
            <year>2006</year>
            <month>Mar</month>
            <day>15</day>
            <volume>242</volume>
            <issue>1-2</issue>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">16448668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Boulton</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Hardman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Embil</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Attinger</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Arag&#x000f3;n-S&#x000e1;nchez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kirsner</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <source>Diagnosis and Management of Diabetic Foot Infections</source>
            <publisher-name>American Diabetes Association</publisher-name>
            <publisher-loc>Arlington (VA)</publisher-loc>
            <year>2020</year>
            <month>01</month>
            <pub-id pub-id-type="pmid">32105420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Boulton</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Bus</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Diabetic Foot Ulcers and Their Recurrence.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Jun</month>
            <day>15</day>
            <volume>376</volume>
            <issue>24</issue>
            <fpage>2367</fpage>
            <page-range>2367-2375</page-range>
            <pub-id pub-id-type="pmid">28614678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpe</surname>
                <given-names>CMO</given-names>
              </name>
              <name>
                <surname>Villar-Delfino</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Dos Anjos</surname>
                <given-names>PMF</given-names>
              </name>
              <name>
                <surname>Nogueira-Machado</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Cellular death, reactive oxygen species (ROS) and diabetic complications.</article-title>
            <source>Cell Death Dis</source>
            <year>2018</year>
            <month>Jan</month>
            <day>25</day>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <pub-id pub-id-type="pmid">29371661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>ZF</given-names>
              </name>
              <name>
                <surname>Cornblath</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>McKhann</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Asbury</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Physiologic-pathologic correlation in Guillain-Barr&#x000e9; syndrome in children.</article-title>
            <source>Neurology</source>
            <year>2000</year>
            <month>Jan</month>
            <day>11</day>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-9</page-range>
            <pub-id pub-id-type="pmid">10636122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stella</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Melito</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Parera</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Del C Batlle</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients.</article-title>
            <source>Int J Biochem Cell Biol</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-7</page-range>
            <pub-id pub-id-type="pmid">8920640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pianta</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Pussell</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Holyday</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cormack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Oct</month>
            <day>06</day>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>1569</fpage>
            <page-range>1569-1577</page-range>
            <pub-id pub-id-type="pmid">28893921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ati&#x0015f;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sevim</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Subclinical peripheral neuropathy associated with chronic obstructive pulmonary disease.</article-title>
            <source>Electromyogr Clin Neurophysiol</source>
            <year>2001</year>
            <season>Apr-May</season>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-91</page-range>
            <pub-id pub-id-type="pmid">11402511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacomis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Neurosarcoidosis.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-36</page-range>
            <pub-id pub-id-type="pmid">22379457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brizzi</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Peripheral nervous system manifestations of infectious diseases.</article-title>
            <source>Neurohospitalist</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>230</fpage>
            <page-range>230-40</page-range>
            <pub-id pub-id-type="pmid">25360209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sghirlanzoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pareyson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lauria</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Sensory neuron diseases.</article-title>
            <source>Lancet Neurol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>349</fpage>
            <page-range>349-61</page-range>
            <pub-id pub-id-type="pmid">15907739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Chronic idiopathic ataxic neuropathy.</article-title>
            <source>Ann Neurol</source>
            <year>1986</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>545</fpage>
            <page-range>545-54</page-range>
            <pub-id pub-id-type="pmid">3014995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Correlation Between Electromyography and Severity and Prognosis of Upper Limb Herpes Zoster.</article-title>
            <source>Pain Physician</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>E749</fpage>
            <page-range>E749-E757</page-range>
            <pub-id pub-id-type="pmid">35901486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wood</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Werter</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Menn</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dellon</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Testing for loss of protective sensation in patients with foot ulceration: a cross-sectional study.</article-title>
            <source>J Am Podiatr Med Assoc</source>
            <year>2005</year>
            <season>Sep-Oct</season>
            <volume>95</volume>
            <issue>5</issue>
            <fpage>469</fpage>
            <page-range>469-74</page-range>
            <pub-id pub-id-type="pmid">16166466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Peripheral neuropathy: clinical and electrophysiological considerations.</article-title>
            <source>Neuroimaging Clin N Am</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-65</page-range>
            <pub-id pub-id-type="pmid">24210312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lefaucheur</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wahab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plant&#x000e9;-Bordeneuve</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>S&#x000e8;ne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>M&#x000e9;nard-Lefaucheur</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rouie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tebbal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salhi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cr&#x000e9;ange</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zouari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ng Wing Tin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of small fiber neuropathy: A comparative study of five neurophysiological tests.</article-title>
            <source>Neurophysiol Clin</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>445</fpage>
            <page-range>445-55</page-range>
            <pub-id pub-id-type="pmid">26596193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thaisetthawatkul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fernandes Filho</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Contribution of QSART to the diagnosis of small fiber neuropathy.</article-title>
            <source>Muscle Nerve</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>883</fpage>
            <page-range>883-8</page-range>
            <pub-id pub-id-type="pmid">23649502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hays</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Utility of skin biopsy to evaluate peripheral neuropathy.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-7</page-range>
            <pub-id pub-id-type="pmid">20425234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bao</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>DQ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>Sensory neuronopathy involves the spinal cord and brachial plexus: a quantitative study employing multiple-echo data image combination (MEDIC) and turbo inversion recovery magnitude (TIRM).</article-title>
            <source>Neuroradiology</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-8</page-range>
            <pub-id pub-id-type="pmid">22922867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antoine</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Robert-Varvat</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maisonobe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cr&#x000e9;ange</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franques</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mathis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delmont</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kuntzer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lefaucheur</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Pouget</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viala</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Desnuelle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Echaniz-Laguna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rotolo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Camdessanch&#x000e9;</surname>
                <given-names>JP</given-names>
              </name>
              <collab>French Neuromuscular Network FILNEMUS</collab>
            </person-group>
            <article-title>Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies.</article-title>
            <source>J Neurol Sci</source>
            <year>2016</year>
            <month>Feb</month>
            <day>15</day>
            <volume>361</volume>
            <fpage>187</fpage>
            <page-range>187-91</page-range>
            <pub-id pub-id-type="pmid">26810539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lakhan</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Velasco</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin-A for Painful Diabetic Neuropathy: A Meta-Analysis.</article-title>
            <source>Pain Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>1773</fpage>
            <page-range>1773-80</page-range>
            <pub-id pub-id-type="pmid">25800040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waldfogel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nesbit</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Dy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Chelladurai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review.</article-title>
            <source>Neurology</source>
            <year>2017</year>
            <month>May</month>
            <day>16</day>
            <volume>88</volume>
            <issue>20</issue>
            <fpage>1958</fpage>
            <page-range>1958-1967</page-range>
            <pub-id pub-id-type="pmid">28341643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singleton</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>K Lessard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Exercise increases cutaneous nerve density in diabetic patients without neuropathy.</article-title>
            <source>Ann Clin Transl Neurol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>10</issue>
            <fpage>844</fpage>
            <page-range>844-9</page-range>
            <pub-id pub-id-type="pmid">25493275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kluding</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Pasnoor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jernigan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rucker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy.</article-title>
            <source>J Diabetes Complications</source>
            <year>2012</year>
            <season>Sep-Oct</season>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>424</fpage>
            <page-range>424-9</page-range>
            <pub-id pub-id-type="pmid">22717465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bodman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dreyer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Varacallo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Diabetic Peripheral Neuropathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">28723038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gawde</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Emmady</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <chapter-title>HIV-1&#x02013;Associated Progressive Polyradiculopathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">32965844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Margolin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shemesh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Toxic and Nutritional Optic Neuropathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">29763154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gwathmey</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of sensory polyneuropathy.</article-title>
            <source>BMJ</source>
            <year>2019</year>
            <month>May</month>
            <day>08</day>
            <volume>365</volume>
            <fpage>l1108</fpage>
            <pub-id pub-id-type="pmid">31068323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of immune-mediated neuropathies.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>1852</volume>
            <issue>4</issue>
            <fpage>658</fpage>
            <page-range>658-66</page-range>
            <pub-id pub-id-type="pmid">24949885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yasaei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Katta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Gabapentin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">29630280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r40">
          <label>40</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cross</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Viswanath</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <chapter-title>Pregabalin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">29261857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dhaliwal</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Spurling</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Molla</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Duloxetine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">31747213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r42">
          <label>42</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Thour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marwaha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Amitriptyline</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30725910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r43">
          <label>43</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Maan</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Duong</surname>
                <given-names>TVH</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Carbamazepine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">29494062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r44">
          <label>44</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Randhawa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wy</surname>
                <given-names>TJP</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Oxcarbazepine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">29493938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28893.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherwani</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Ekhzaimy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sakharkar</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients.</article-title>
            <source>Biomark Insights</source>
            <year>2016</year>
            <volume>11</volume>
            <fpage>95</fpage>
            <page-range>95-104</page-range>
            <pub-id pub-id-type="pmid">27398023</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
